The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes
Non-Alcoholic Fatty Liver Disease in Gestational Diabetes - An Opportunity for Prevention of Type 2 Diabetes Mellitus?
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
A liver ultrasound will be completed during the last trimester of pregnancy along with a questionnaire. The questionnaire includes baseline maternal characteristics, age, race, ethnicity, parity, blood pressure, pulse, medications, activity level, sociodemographic and behavioral risk factors, pregravid BMI, previous obstetric history, medical and family history.
The subject will come in person to clinic two times after the subject has had her baby (at 6 weeks postpartum, and at 6 months postpartum).
The subject will give blood samples during the 6 weeks postpartum visit and 6 months postpartum visit, and an Oral Glucose Tolerance Test will be done at these visits. Blood samples will be drawn by putting a small needle or IV catheter (a small plastic tube) into a vein in the subject's arm. Blood samples will be obtained at timed intervals both before and after the subject is given a glucose beverage to drink, to see how well the subject's body deals with sugar in the blood over time. The total amount of blood to be drawn for each Oral Glucose Tolerance Test and research blood work will be approximately 90 ml (about 6 tablespoons). The total volume of blood taken over the course of the study for each subject will be approximately 180 ml (about 12 tablespoons).
The subject will have their blood pressure measured with a blood pressure cuff during each clinic visit. The height, weight and pulse rate will also be measured. This will take about five minutes.
The subject will have an ultrasound of her liver at the 6 week postpartum visit and 6 month postpartum visit. This will take about 30 to 60 minutes each time.
The investigator's study coordinator will call the subject to do a questionnaire over the phone at 3 months after the subject has had the baby. During the phone call, the study coordinator will ask the subject how the baby is being fed. The study coordinator will also update information about development of any new medical problems and medications the subject's doctor might have started, activity levels, and health habits. Subjects will be asked questionnaires to update this information during their 6 week postpartum and 6 month postpartum clinic visits as well.
The subject's understanding and approval of these procedures is required if she is to participate in this study.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32608
- Shands Medical Plaza
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
- a pregnant female
- age between 18-50 years.
Beskrivelse
Inclusion Criteria:
- a pregnant female
- age between 18-50 years.
Exclusion Criteria:
- pregravid diabetes mellitus
- inability to understand and speak English
- inability to provide consent
- plans to relocate out of the area within 12 months postpartum
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Subjects with Gestational Diabetes
Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
|
Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
Andre navne:
|
|
Controls without Gestational Diabetes
Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
|
Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of patients with NAFLD and gestational diabetes.
Tidsramme: 6 months
|
Patients with gestational diabetes will be screened for fatty liver by ultrasound to estimate the prevalence of NAFLD in this population.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Insulin sensitivity expressed as the Matsuda Index, measured during an oral glucose tolerance test (OGTT).
Tidsramme: At 6 weeks and 6 months after delivery
|
Patients will undergo an OGTT at 6 weeks and 6 months after delivery to measure their insulin sensitivity (which will be expressed as Matsuda Index).
|
At 6 weeks and 6 months after delivery
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Maryam Sattari, MD, University of Florida
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB201600437
- 375-2012 (Anden identifikator: University of Florida)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Svangerskabsdiabetes mellitus under graviditet
-
Sansum Diabetes Research InstituteAfsluttetDiabetes mellitus, type 2 | Diabetes Mel Gestational - under graviditetForenede Stater
-
Lahore University of Biological and Applied SciencesIkke rekrutterer endnuGraviditetskomplikationer | Svangerskabsdiabetes mellitus (GDM) | Diabetes under graviditet | Graviditet ved diabetes | Gestational | Diabetes KomplikationPakistan
-
Women and Infants Hospital of Rhode IslandIkke rekrutterer endnuSvangerskabsdiabetes | Lille-til-gestational alder | Neonatal hypoglykæmi | Maternel fedme komplicerer graviditet | Stor-for-gestational alder
-
Assistance Publique - Hôpitaux de ParisUnité de Recherche Clinique Necker Cochin, FranceAfsluttet
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho... og andre samarbejdspartnereSuspenderetGraviditetskomplikationer | Fedme, moder | Diabetes Mel Gestational - under graviditetBrasilien
-
Shandong UniversityShengjing Hospital; General Hospital of Ningxia Medical University; West... og andre samarbejdspartnereRekrutteringPrædiabetes | Metformin | In-vitro-befrugtningKina
-
Assiut UniversityUkendtom Vitreomacular Interface Abnormalities in Diabetic Retinopathy